NASDAQ$SCPH
scPharmaceuticals Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
scPharmaceuticals reported its second quarter 2023 financial results and provided a business update.
scPharmaceuticals reported net FUROSCIX revenue of $1.6 million and ended the quarter with $102.9 million in cash, cash equivalents and short-term investments. The company is also planning to file for NYHA Class IV indication expansion by the end of 2023.
- Generated net FUROSCIX revenue of $1.6 million.
- Ended Q2 2023 with cash, cash equivalents and short-term investments of $102.9 million.
- Added 10 sales territories at the end of Q2, bringing the total field force to 54 territories.
- Plans to file for NYHA Class IV indication expansion by the end of 2023.
Headline financials
Revenue & EPS history
scPharmaceuticals · Revenue · Quarterly
$1.64M
Revenue by segment
scPharmaceuticals · $1.6M total across 1 segment · Q2 2023
- FUROSCIX$1.6M—100.0%
Forward guidance
scPharmaceuticals is focused on expanding coverage of FUROSCIX and expanding the FUROSCIX label to include NYHA Class IV heart failure patients.
Tailwinds
- Positive coverage and a preferred formulary decision by a top five national commercial health plan, effective June 1
- National Medicaid coverage effective July 1
- Encouraging Type C meeting feedback from the FDA that opens the door to potential indication expansion to also include NYHA Class IV patients.
- Well funded, with approximately $102.9 million of cash, cash equivalents and investments
- Adding additional territories opportunistically as warranted to maximize geographic coverage and patient access to FUROSCIX
Headwinds
- Risk of any unforeseen delays or setbacks in the commercialization of FUROSCIX
- Risk of the ability of the FUROSCIX On-Body Infusor to appropriately deliver therapy
- Risk of the receipt of regulatory approval for any of our product candidates or, if approved, the successful commercialization of such products
- Risks related to manufacturing and quality assurances processes
- Risk that global economic factors and uncertainties, including as a result of the COVID-19 pandemic, will impact the Company’s operations
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports
+3.8%
Avg return
Earnings day
+5.8%
Avg return
5 days after
+7.1%
Avg return
30 days after
52%
16 / 31 earnings
Positive
+52.7%
Q4 2019
Best reaction
-14.5%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | -7.4% | -4.6% | +11.6% | |
| Q1 2025 | +27.4% | +45.1% | +74.8% | |
| Q4 2024 | -1.0% | -1.3% | -15.5% | |
| Q3 2024 | -14.5% | -14.8% | -18.6% | |
| Q2 2024 | +2.6% | +3.7% | +11.8% | |
| Q1 2024 | +5.1% | +10.6% | -6.9% | |
| Q4 2023 | -1.1% | +2.2% | -7.8% | |
| Q3 2023 | -8.4% | — | — | |
| Q2 2023 | +0.0% | — | — | |
| Q1 2023 | -0.6% | — | — | |
| Q4 2022 | +25.0% | — | — | |
| Q3 2022 | +7.3% | — | — | |
| Q2 2022 | +8.6% | — | — | |
| Q1 2022 | +7.7% | — | — | |
| Q4 2021 | +7.0% | — | — | |
| Q3 2021 | -10.1% | — | — | |
| Q2 2021 | +4.9% | — | — | |
| Q1 2021 | -5.3% | — | — | |
| Q4 2020 | -6.6% | — | — | |
| Q3 2020 | +2.0% | — | — | |
| Q2 2020 | +0.0% | — | — | |
| Q1 2020 | -4.0% | — | — | |
| Q4 2019 | +52.7% | — | — | |
| Q3 2019 | -5.4% | — | — | |
| Q2 2019 | +10.1% | — | — | |
| Q1 2019 | +0.6% | — | — | |
| Q4 2018 | -4.8% | — | — | |
| Q3 2018 | +1.2% | — | — | |
| Q2 2018 | +2.9% | — | — | |
| Q1 2018 | +29.2% | — | — | |
| Q4 2017 | -6.7% | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro